| Oncometabolites suppress DNA repair by disrupting local chromatin signalling PL Sulkowski, S Oeck, J Dow, NG Economos, L Mirfakhraie, Y Liu, ... Nature 582 (7813), 586-591, 2020 | 263 | 2020 |
| Krebs-cycle-deficient hereditary cancer syndromes are defined by defects in homologous-recombination DNA repair PL Sulkowski, RK Sundaram, S Oeck, CD Corso, Y Liu, S Noorbakhsh, ... Nature genetics 50 (8), 1086-1092, 2018 | 206 | 2018 |
| Protein expression and functional relevance of efflux and uptake drug transporters at the blood–brain barrier of human brain and glioblastoma X Bao, J Wu, Y Xie, S Kim, S Michelhaugh, J Jiang, S Mittal, N Sanai, J Li Clinical Pharmacology & Therapeutics 107 (5), 1116-1127, 2020 | 64 | 2020 |
| A phase 0 trial of ribociclib in recurrent glioblastoma patients incorporating a tumor pharmacodynamic-and pharmacokinetic-guided expansion cohort AC Tien, J Li, X Bao, A Derogatis, S Kim, S Mehta, N Sanai Clinical Cancer Research 25 (19), 5777-5786, 2019 | 62 | 2019 |
| Pharmacometabolomics reveals irinotecan mechanism of action in cancer patients X Bao, J Wu, S Kim, P LoRusso, J Li The Journal of Clinical Pharmacology 59 (1), 20-34, 2019 | 61 | 2019 |
| Quantitative and mechanistic understanding of AZD1775 penetration across human blood–brain barrier in glioblastoma patients using an IVIVE–PBPK modeling approach J Li, J Wu, X Bao, N Honea, Y Xie, S Kim, A Sparreboom, N Sanai Clinical Cancer Research 23 (24), 7454-7466, 2017 | 60 | 2017 |
| Gold nanoparticle conjugated Rad6 inhibitor induces cell death in triple negative breast cancer cells by inducing mitochondrial dysfunction and PARP-1 hyperactivation … B Haynes, Y Zhang, F Liu, J Li, S Petit, H Kothayer, X Bao, AD Westwell, ... Nanomedicine: Nanotechnology, Biology and Medicine 12 (3), 745-757, 2016 | 52 | 2016 |
| Novel Pyrrolo[3,2-d]pyrimidine Compounds Target Mitochondrial and Cytosolic One-carbon Metabolism with Broad-spectrum Antitumor Efficacy AS Dekhne, K Shah, GS Ducker, JM Katinas, J Wong-Roushar, ... Molecular cancer therapeutics 18 (10), 1787-1799, 2019 | 51 | 2019 |
| Evaluation of hybrid theoretical approaches for structural determination of a glycine-linked cisplatin derivative via infrared multiple photon dissociation (IRMPD) action … CC He, B Kimutai, X Bao, L Hamlow, Y Zhu, SF Strobehn, J Gao, ... The Journal of Physical Chemistry A 119 (44), 10980-10987, 2015 | 38 | 2015 |
| Amino acid-linked platinum (II) analogues have altered specificity for RNA compared to cisplatin K Rijal, X Bao, CS Chow Chemical Communications 50 (30), 3918-3920, 2014 | 38 | 2014 |
| Physiologically based pharmacokinetic modeling of central nervous system pharmacokinetics of CDK4/6 inhibitors to guide selection of drug and dosing regimen for brain cancer … J Li, J Jiang, J Wu, X Bao, N Sanai Clinical Pharmacology & Therapeutics 109 (2), 494-506, 2021 | 30 | 2021 |
| Determination of total and unbound ribociclib in human plasma and brain tumor tissues using liquid chromatography coupled with tandem mass spectrometry X Bao, J Wu, N Sanai, J Li Journal of pharmaceutical and biomedical analysis 166, 197-204, 2019 | 27 | 2019 |
| A liquid chromatography with tandem mass spectrometry method for quantitating total and unbound ceritinib in patient plasma and brain tumor X Bao, J Wu, N Sanai, J Li Journal of pharmaceutical analysis 8 (1), 20-26, 2018 | 22 | 2018 |
| Strategy for tumor-selective disruption of androgen receptor function in the spectrum of prostate cancer R Rosati, L Polin, C Ducker, J Li, X Bao, D Selvakumar, S Kim, B Xhabija, ... Clinical Cancer Research 24 (24), 6509-6522, 2018 | 18 | 2018 |
| Nano-delivery of RAD6/Translesion Synthesis Inhibitor SMI#9 for Triple-negative Breast Cancer Therapy N Saadat, F Liu, B Haynes, P Nangia-Makker, X Bao, J Li, LA Polin, ... Molecular cancer therapeutics 17 (12), 2586-2597, 2018 | 18 | 2018 |
| Discovery of 6-substituted thieno [2, 3-d] pyrimidine analogs as dual inhibitors of glycinamide ribonucleotide formyltransferase and 5-aminoimidazole-4-carboxamide … A Wallace-Povirk, N Tong, J Wong-Roushar, C O'Connor, X Zhou, Z Hou, ... Bioorganic & medicinal chemistry 37, 116093, 2021 | 17 | 2021 |
| Mechanistic modeling of central nervous system pharmacokinetics and target engagement of HER2 tyrosine kinase inhibitors to inform treatment of breast cancer brain metastases J Li, J Jiang, X Bao, V Kumar, SC Alley, S Peterson, AJ Lee Clinical Cancer Research 28 (15), 3329-3341, 2022 | 16 | 2022 |
| A phase 0 trial of ceritinib in patients with brain metastases and recurrent glioblastoma S Mehta, R Fiorelli, X Bao, C Pennington-Krygier, A Derogatis, S Kim, ... Clinical Cancer Research 28 (2), 289-297, 2022 | 14 | 2022 |
| Co-targeting of HDAC, PI3K, and Bcl-2 results in metabolic and transcriptional reprogramming and decreased mitochondrial function in acute myeloid leukemia KH Hurrish, X Qiao, X Li, Y Su, J Carter, J Ma, HA Kalpage, M Hüttemann, ... Biochemical pharmacology 205, 115283, 2022 | 12 | 2022 |
| Quantitative protein expression of blood‐brain barrier transporters in the vasculature of brain metastases of patients with lung and breast cancer X Bao, J Wu, J Jiang, AC Tien, N Sanai, J Li Clinical and translational science 14 (4), 1265-1271, 2021 | 12 | 2021 |
